November 13, 2013
Kyowa Hakko Kirin said on November 11 that it will discontinue its PII clinical study for bardoxolone methyl (development code: RTA 402), an investigational drug licensed from a US biotech startup, in chronic kidney disease patients with type 2 diabetes...read more